Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-22
2011-03-22
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S120000
Reexamination Certificate
active
07910602
ABSTRACT:
The invention relates to 6-amido substituted pyrazolopyridine derivatives of the formula (I)useful as inhibitors of beta-adrenergic receptor kinase 1 (βARK-1), compositions containing such compounds and their use for the treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction.
REFERENCES:
patent: 99-30710 (1999-06-01), None
patent: WO 03-068773 (2003-08-01), None
patent: WO 2004-014910 (2004-02-01), None
patent: WO 2004-076450 (2004-09-01), None
Tomaszewski et al., Hypertension, (Nov. 2004) vol. 44, No. 5, pp. 689-694.
Lynch, Pyrazolo[3,4-b]pyridines: syntheses, eractions, and nuclear magnetic resonance spectra, Can. J. of Chem.; 1988; 66(3); p. 426.
Bjergarde Kirsten
Huber Jochen
Patek Marcel
Pirard Bernard
Ritter Kurt
Farquharson-Torres Serena
Rahmani Niloofar
Sanofi-Aventis
Scully, Scott, Murphy and Presser, P.C.
Seaman D. Margaret
LandOfFree
Pyrazolopyridine derivatives as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolopyridine derivatives as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyridine derivatives as inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2618804